PDF DatasheetAntibody (Suitable for clinical applications)
| Specification | Recommendation |
|---|---|
| Recommended Dilution (Conc) | 1:50-1:100 |
| Pretreatment | EDTA Buffer pH 8.0 |
| Incubation Parameters | 30 min at Room Temperature |
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
Bcl-2 Oncoprotein Information for Pathologists
Summary:
BCL2 is a proto-oncogene at locus 18q21.3 the plays a role in inhibiting apoptosis. The BCL2 protein has a M.W. of 25 kDa.
Common Uses By Pathologists:
BCL2 staining is used to distinguish follicular hyperplasia of lymph node (germinal centers are BCL2 negative) from follicular lymphoma (germinal centers are BCL2 positive). However, there are reported cases of follicular lymphomas that are BCL2 negative (Am J Surg Pathol 2011;35:1691, Am J Surg Pathol 2009;33:591). BCL2 staining can also identify immature enteric ganglion cells in pediatric intestinal pseudo-obstruction (Am J Surg Pathol 2005;29:1017). BCL2 antibodies label diffuse large cell lymphoma which is an adverse prognostic factor in some studies (Mod Pathol 2005;18:1113, Clin Cancer Res 2011;15:7785). Myelodysplastic syndrome patients should be screened for BCL2 as increased expression is associated with progression. Finally, BCL2 may have prognostic value in early stage breast cancer (Br J Cancer 2010;103:668).
| Bcl-2 Oncoprotein General Information | |
|---|---|
| Alternate Names | |
| Molecular Weight | |
| 26.3 kDa | |
| Chromosomal Location | |
| q21.33 [chr: 18] [chr_start: 63123346] [chr_end: 63320128] [strand: -1] | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | BCL2 |
| Entrez Gene ID | 596 |
| RefSeq Protein Accession(s) | NP_000648; NP_000624 |
| RefSeq mRNA Accession(s) | XM_011526135; NM_000633; XR_935248; XM_017025917; NM_000657 |
| RefSeq Genomic Accession(s) | NG_009361; NC_000018 |
| UniProt ID(s) | P10415 |
| PharmGKB ID(s) | PA25302 |
| KEGG Gene ID(s) | hsa:596 |
| Associated Diseases (KEGG IDs) | A chromosomal aberration involving BCL2 has been found in chronic lymphatic leukemia. Translocation t(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutations found in non-Hodgkin lymphomas carrying the chromosomal translocation could be attributed to the Ig somatic hypermutation mechanism resulting in nucleotide transitions. {ECO:0000269|PubMed:2875799, ECO:0000269|PubMed:3285301}. |
| General Description of Bcl-2 Oncoprotein . | |
| The bcl-2 product is considered to act as an inhibitor of apoptosis. Bcl-2 expression is inhibited in germinal centers where apoptosis forms part of the B cell production pathway. Reactive follicles show no staining for bcl-2, whereas the cells in neoplastic follicles exhibit membrane staining. Bcl-2 alpha oncoprotein has been shown to inhibit apoptosis. | |
There are no reviews yet.